Time-restricted feeding for pancreatic cancer prevention
Active Awarded Last action
- Contract number
- 75N91024F00002
- Awardee
-
The Univeristy Of Texas M.d. Anderson Cancer Center UEI S3GMKS8ELA16
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $551,730
Award facts
- Opportunity
-
- TORFP2024E02 Solicitation number
- Contract value 48% obligated
-
- $551,730.00 Current, with exercised options
- $1,144,300.00 Potential, with all options
- Completion date 93% complete
- Current and potential, with all options
- NAICS code
- 541714 Research and Development in Biotechnology (except Nanobiotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
- Place of performance
- Houston, TX 77030, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Supplemental Agreement for work within scope | $0 | |
| Original award | $551,730 |
About this award
The National Cancer Institute awarded a $1.14M firm fixed-price delivery order to The University of Texas MD Anderson Cancer Center for research on time-restricted feeding as a potential pancreatic cancer prevention strategy. This delivery order is part of MD Anderson's larger $149.995B Preclinical Efficacy & Intermediate Endpoint Biomarkers Indefinite Delivery/Indefinite Quantity (IDIQ) contract with NCI, which remains active through January 2029 and supports comprehensive preclinical evaluation of potential cancer preventive agents. The work will be performed in Houston, Texas, with an ultimate completion date of December 19, 2026. No set-aside designation was used for this award, reflecting MD Anderson's competitive standing as a premier academic research institution.
As a National Cancer Institute-designated Comprehensive Cancer Center and component of the University of Texas System, MD Anderson brings substantial expertise in translational cancer research and preclinical drug development to this engagement. The delivery order structure under the parent IDIQ vehicle enables NCI to efficiently task specific research projects while maintaining program oversight and a defined ceiling framework. This award reflects NCI's confidence in MD Anderson's established capabilities in executing complex preclinical research programs that advance the agency's cancer prevention research agenda, consistent with the center's track record of delivering specialized cancer research services across multiple federal funding mechanisms.
Quick answers
Who was awarded contract 75N91024F00002?
75N91024F00002 was awarded to The Univeristy Of Texas M.d. Anderson Cancer Center by National Cancer Institute (National Institutes of Health) on September 20, 2024.
How much is contract 75N91024F00002 worth?
The government has obligated $551,730 on 75N91024F00002. Its potential value, with all options, is $1,144,300.
Is contract 75N91024F00002 an order under another contract?
Yes. 75N91024F00002 is a delivery order under 75N91024D00004, an indefinite delivery contract, on PRECLINICAL EFFICACY & INTERMEDIATE ENDPOINT BIOMARKERS IDIQ.
Was contract 75N91024F00002 competed?
The extent of competition for 75N91024F00002 was full and open competition. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award